RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
1.330
-0.020 (-1.48%)
Jan 22, 2026, 2:40 PM EST - Market open
RedHill Biopharma Revenue
RedHill Biopharma had revenue of $2.04M in the half year ending June 30, 2025, with 58.59% growth. This brings the company's revenue in the last twelve months to $9.55M, up 157.62% year-over-year. In the year 2024, RedHill Biopharma had annual revenue of $8.04M with 23.17% growth.
Revenue (ttm)
$9.55M
Revenue Growth
+157.62%
P/S Ratio
0.22
Revenue / Employee
$272,857
Employees
35
Market Cap
6.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.04M | 1.51M | 23.17% |
| Dec 31, 2023 | 6.53M | -55.27M | -89.43% |
| Dec 31, 2022 | 61.80M | -23.96M | -27.94% |
| Dec 31, 2021 | 85.76M | 21.40M | 33.25% |
| Dec 31, 2020 | 64.36M | 58.07M | 923.03% |
| Dec 31, 2019 | 6.29M | -2.07M | -24.75% |
| Dec 31, 2018 | 8.36M | 4.35M | 108.63% |
| Dec 31, 2017 | 4.01M | 3.91M | 3,867.33% |
| Dec 31, 2016 | 101.00K | 98.00K | 3,266.67% |
| Dec 31, 2015 | 3.00K | -7.01M | -99.96% |
| Dec 31, 2014 | 7.01M | 7.00M | 58,350.00% |
| Dec 31, 2013 | 12.00K | -4.00K | -25.00% |
| Dec 31, 2012 | 16.00K | -7.00K | -30.43% |
| Dec 31, 2011 | 23.00K | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Flora Growth | 57.61M |
| IM Cannabis | 37.61M |
| Sunshine Biopharma | 37.32M |
| Biofrontera | 37.16M |
| cbdMD | 19.19M |
| Sonoma Pharmaceuticals | 16.94M |
| InMed Pharmaceuticals | 4.80M |
| China Pharma Holdings | 4.05M |
RDHL News
- 16 days ago - What's Going On With Redhill Biopharma Stock On Tuesday? - Benzinga
- 17 days ago - RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects - PRNewsWire
- 5 weeks ago - RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells - PRNewsWire
- 7 weeks ago - RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement - PRNewsWire
- 2 months ago - RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement - PRNewsWire
- 3 months ago - RedHill Biopharma Receives Nasdaq Staff Determination Notification - PRNewsWire
- 3 months ago - CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO - PRNewsWire
- 3 months ago - RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® - PRNewsWire